Structure Therapeutics Inc. (NASDAQ:GPCR) ranks fifth in the Top 10 AI-Powered Biotech Stocks to Buy Now. The company focuses on developing oral small-molecule therapies for metabolic diseases like obesity and diabetes, using AI-powered drug discovery for speed and precision in candidate design.

Structure Therapeutics Inc. (NASDAQ:GPCR) is advancing its lead obesity candidate, aleniglipron, through two Phase 2b studies, with topline results expected by year-end 2025. The company also plans Phase 1 trials for ACCG-2671, an oral amylin receptor agonist, to expand its metabolic disease portfolio. Financially, it reported a net loss of $61.7 million in Q2 2025 but has a strong cash position supporting operations through 2027.

The firm’s AI-driven approach focuses on orally available therapies, potentially improving patient accessibility and compliance. With pivotal Phase 2b readouts approaching for aleniglipron and upcoming ACCG-2671 trials, Structure Therapeutics Inc. demonstrates the power of AI integration in accelerating drug discovery for obesity and metabolic disorders.

While Structure Therapeutics Inc. (NASDAQ:GPCR) shows promise as an investment, other AI stocks may offer higher upside potential with lower downside risk. For those seeking an undervalued AI stock benefiting from current trends, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Structure Therapeutics Inc. (GPCR) Eyes Major 2025 Catalyst With Phase 2b Obesity Data